Key result
The de Groot Score best predicts GI bleeding in antiplatelet users with ~0.88 AUC.
Why the study?
Gastrointestinal bleeding is a common serious complication of antiplatelet therapy, but no specific bleeding risk scores were available for East Asian patients.
Does the de Groot Score better predict gastrointestinal bleeding in East Asian patients on antiplatelet therapy compared to other risk scores?
Cohort (n=4,052)
Yes
Does the de Groot Score better predict gastrointestinal bleeding in East Asian patients on antiplatelet therapy compared to other risk scores?
The de Groot Score demonstrates superior predictive value for gastrointestinal bleeding in Chinese patients on antiplatelet therapy compared to other established risk scores.
May aid GIB risk stratification in Chinese antiplatelet patients; hypothesis-generating and requires prospective validation before practice change.
Gastrointestinal bleeding (GIB) is the most common serious bleeding complication of antiplatelet therapy. The bleeding risk score (BRS) of GIB may help to determine the risk of bleeding, and provides a reference for the formulation of antiplatelet therapy regimen in clinical practice, but we found that no specific risk scores are available in East Asian patients. This study analyzed patients who were administered antiplatelet therapy from May 2015 to December 2018 in two medical centers. Patient’s baseline data were obtained. We assessed four BRSs (New Score, RIETE Score, Cuschieri Score, de Groot Score) and compared them using the area under the receiver operating characteristic curve (AUC). The 4,052 patients enrolled in this study had an average age of 69.6 ± 10.8 years, and 65.9% of them were male. Among the 4,052 patients included, 171 patients experienced GIB within 6 months of follow-up. In the study population, the AUCs for the New, RIETE, Cuschieri, and de Groot scores were 0.673 (95% confidence interval (CI) 0.616–0.729, P < .001), 0.742 (95% CI 0.690–0.794, P < .001), 0.598 (95% CI 0.537–0.659, P = .002), and 0.875 (95% CI 0.839–0.912, P < .001), respectively. After validation, the de Groot Score has better performance. Among the four scores, the de Groot Score might be more suitable for helping Chinese clinicians to predict the risk of GIB in patients taking antiplatelet drugs, and reduce GIB events.
No takes yet. Share an insight, caveat, or question.
Lv et al. (2021) conducted a cohort in Patients on antiplatelet therapy (n=4,052). de Groot Score vs. New Score, RIETE Score, Cuschieri Score was evaluated on Predictive value for gastrointestinal bleeding (AUC) (AUC 0.875, 95% CI 0.839-0.912, p=< .001). The de Groot Score demonstrated the best performance among four risk scores for predicting gastrointestinal bleeding in patients on antiplatelet therapy (AUC 0.875; 95% CI 0.839-0.912; P<.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: